GATA3

Assessments
Characteristics
Multifunctional transcription factor.
Neoplasms
+: >90% positive, +/-: 50-90% positive, -/+: 10 - >50% positive, -(+): 1-<10% positive, -: <1% positive, ?: conflicting evidence or insufficient information. + Lobular breast carcinoma (100%), yolk sac tumour and choriocarcinoma (100%) +/- Estrogen receptor or HER2 positive ductal breast carcinoma (estrogen receptor and HER2 positive ~90%, triple negative ~60%), urothelial carcinoma and squamous cell carcinoma of skin (~80%), malignant mesothelioma (~60%), chromophobic renal cell carcinoma (~50%) -/+ Salivary gland carcinomas (~40%), pancreas adenocarcinoma (~40%?), squamous cell carcinoma of uterine cervix (~30%), larynx (~20%), and lung (~10%) -(+) Adenocarcinomas of stomach, colon, prostate, endometrium (<10%), various sarcomas. - Adenocarcinomas apart from the above mentioned, endocrine tumours.
Application
Identification of breast carcinoma and urothelial carcinoma.
Controls
Kidney and tonsil is recommended as positive and negative tissue controls for GATA3. In kidney, moderate to strong nuclear staining reaction in virtually all epithelial cells lining the collecting ducts and podocytes in glomeruli must be seen. In tonsil the vast majority of T-cells in the T-zones must show an at least weak but distinct nuclear staining reaction. No staining of B-cells should be seen (dispersed intra-germinal Tcells will be identified).
26.07.15 - MV/LE